For years, Novo Nordisk was the poster child of growth. Its GLP-1 drugs, Ozempic and Wegovy, didn’t just change obesity treatment — they reshaped the company’s balance sheet. Demand outpaced supply, public awareness skyrocketed, and Novo’s market cap surged. But growth always attracts challengers. Enter Eli Lilly with Mounjaro and Zepbound, and a wave of competitors and compounded generics threatening margins. Add in slowing sales growth and operational bloat from years of expansion, and suddenly Novo’s leadership had to answer tough questions about sustainability.

Healthcare Marketing in the Covid-19 Era

How should healthcare business leaders (pharma, devices, diagnostics, disposables...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Precision Farming Market to Witness Promising Growth Opportunities by 2024-2035

Driven by the ongoing efforts to overcome the inefficiencies...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

Marketing

Precision Farming Market to Witness Promising Growth Opportunities by 2024-2035

Driven by the ongoing efforts to overcome the inefficiencies...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

Policies/Sales

Precision Farming Market to Witness Promising Growth Opportunities by 2024-2035

Driven by the ongoing efforts to overcome the inefficiencies...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

Strategy

Precision Farming Market to Witness Promising Growth Opportunities by 2024-2035

Driven by the ongoing efforts to overcome the inefficiencies...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Does Public-Private Partnership Benefit The Public?

Does This Public-Private Partnership Benefit The Public?” (Tuesday, July...

Novo Nordisk to Acquire Akero Therapeutics for $4.7 Billion

Novo Nordisk has announced plans to acquire Akero Therapeutics...

Navigating India’s Diverging Health Landscape and Field Force Optimisation

India’s health map is splitting into two distinct opportunity...

If Strategy is Commodity, How Can Organisations Ensure Differentiation?

Strategy and strategic planning are perhaps the most hyped-up...

DiME (Digi MarketEr):-TiME to SHiNE

The new sparkling DIME (Digi MarketEr) are the ones who embrace digital transformation with open arms and voraciously feed on data analytics to satisfy their performance outcomes with an informed business decision. The benefit of being DIME is that it propels data management out of the hands of individual stakeholders, and puts data sets with insights on to center glass table (Transparent workplace) for informed decision making.